Pharma News

Teva to buy Auspex Pharma, reinforcing CNS portfolio

Home/Pharma News | Posted 10/04/2015

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 30 March 2015 that it would buy US biopharmaceutical company Auspex Pharmaceuticals (Auspex) for an equity value of US$3.5 billion.

India to set up pharma manufacturing clusters

Home/Pharma News | Posted 03/04/2015

The Indian Government is planning to set up pharmaceutical manufacturing clusters in order to reduce costs and make the industry more competitive.

Boehringer Ingelheim loses patent battle with India’s Cipla

Home/Pharma News | Posted 20/03/2015

German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.

Indian Government to launch own brand of generics

Home/Pharma News | Posted 06/03/2015

Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.

Canada clamps down on companies failing to post drug shortage information

Home/Pharma News | Posted 27/02/2015

The Canadian Government has made it mandatory for drug companies to report actual and anticipated drug shortages. A voluntary system that had been in place was not working well enough, said the country’s Health Minister, Rona Ambrose.

Pfizer sets to lead biosimilars and generics markets

Home/Pharma News | Posted 20/02/2015

Pharma giant Pfizer has announced it is to buy injectable generics specialist and biosimilars maker Hospira for US$17 billion. The products acquired in the deal will be integrated into Pfizer’s generics unit, Global Established Pharmaceutical (GEP).

Mylan on track to acquire Abbott generics and expand role in women’s health

Home/Pharma News | Posted 13/02/2015

The European Commission (EC) has approved Mylan’s acquisition of Abbott Laboratories' Non-US Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM), subject to conditions. US-based generics manufacturer Mylan will have to sell off a number of its businesses in France, Germany, Ireland, Italy and UK in order to satisfy European Union merger regulations.

Actavis to buy UK generics maker Auden McKenzie

Home/Pharma News | Posted 06/02/2015

US generics maker Actavis announced on 26 January 2015 that it had agreed to buy UK generics maker Auden McKenzie. The deal will propel Actavis into the top position in the UK for generics suppliers, placing it in third position in the UK overall.

Amgen’s approach in the biosimilars market

Home/Pharma News | Posted 23/01/2015

Biotech giant Amgen now has a biosimilars programme that includes nine different molecules [1]. A representative from Amgen has spoken to GaBI about the company’s venture into biosimilars [2].

Cipla makes deal with Serum Institute for vaccines in Europe

Home/Pharma News | Posted 05/12/2014

India-based generics maker Cipla announced on 20 November 2014 that it had signed a deal with the Serum Institute of India (Serum Institute) to distribute vaccines in Europe.

Actavis buys Allergan and joins pharma top 10

Home/Pharma News | Posted 28/11/2014

On 17 November 2014, US generics maker Actavis announced that the company had made a deal to acquire botox-maker Allergan for US$66 billion.

Xbrane signs biosimilar optimization deal with Indian pharma firm

Home/Pharma News | Posted 14/11/2014

Swedish biotech company Xbrane Bioscience (Xbrane) has signed an agreement with a global Indian pharmaceutical company to assist them in developing an optimized production system for a specific biosimilar that will be marketed worldwide. The aim is to help the client reduce production costs in order to gain a competitive advantage in the biosimilar market.

Cipla Medpro to collaborate with Teva for generics in South Africa

Home/Pharma News | Posted 07/11/2014

India-based generics maker Cipla announced on 8 October 2014 that it had made a collaboration deal with Israel’s Teva Pharmaceuticals for sales and distribution of the latter’s generic drugs in South Africa.

Supernus sues Actavis over generic Trokendi XR

Home/Pharma News | Posted 31/10/2014

US-based central nervous system specialist Supernus Pharmaceuticals (Supernus) announced on 2 Oct 2014 that it had sued generics maker Actavis for infringement of three patents covering its antiepileptic drug Trokendi XR (extended release topiramate). The three US patents (8,298,576, 8,298,580, and 8,663,683) cover once-a-day topiramate formulations and methods of treating seizures using those formulations.

Generics maker IGI Labs gains rights to AstraZeneca injectables

Home/Pharma News | Posted 17/10/2014

Speciality topical generics maker IGI Laboratories (IGI Labs) announced on 25 September 2014 that it had acquired the rights for 18 drugs from AstraZeneca.

India suffers HIV drug shortages

Home/Pharma News | Posted 10/10/2014

Supply bottlenecks and late payments to drugmakers have hit HIV treatment supplies across India, according to reports in the Indian press. The drug shortages, which affect those least able to pay, have seen some government distribution centres running out of drugs altogether.

Biocad to be taken over by Russian investment firm

Home/Pharma News | Posted 02/06/2014

Russia’s biggest drugmaker, Pharmstandard, and investment company, Millhouse LLC, have said that they are planning to buy 70% of Russian biosimilars developer Biocad.

Amgen and Pfizer seek deal with Russian non-originator biologicals firm

Home/Pharma News | Posted 30/08/2013

Russian biotechnology company Biocad is reported to be attracting offers from US-based Pfizer and biotechnology giant Amgen.

Strides and Shasun merger aims to spread risk

Home/Pharma News | Posted 03/10/2014

In the current climate of increasing scrutiny against Indian generics manufacturers by the US Food and Drug Administration (FDA), Indian generics maker Strides Arcolab (Strides) and India-based active pharmaceutical ingredient (API) maker Shasun Pharmaceuticals (Shasun) have announced a ‘risk-spreading’ merger.

Generics and biosimilars Initiative

News

Research

General